Among other things, angio-MR is playing an increasingly important role in pre-revascularisation

assessments of the vascular tree because the new-generation coils make it possible to obtain panoramic views from the intracranial circulation to the plantar arch and avoid the use of nephrotoxic contrast media. MR is highly sensitive and specific in the various vascular districts, and its performance is similar to that of standard angiography at the level of the iliac aorta, the femoro-popliteal high throughput screening assay axis and the renal and carotid arteries. Its main limitations are related to venous contamination of the foot, the lack of information concerning the type of plaque causing the stenosis/obstruction (calcified, lipid or fibrous), the absence of signal in the presence of ferromagnetic artefacts (metal stents and arthroprostheses) and the general contraindications to MR such as pacemakers, claustrophobia,

etc [70]. Multilayer angio-CT is currently considered the gold standard in most vascular districts, where its sensitivity and specificity are similar to those of arteriography. It optimally characterises the type of plaque causing the stenosis/obstruction and therefore makes it possible to choose the most suitable technique and material for each individual procedure, and it provides more information than MR concerning the surrounding parenchyma and the presence of associated co-morbidities. Furthermore, technological advances have reduced acquisition times to a minimum (a few seconds) and reduced the radiation Smad inhibitor dose to acceptable levels. The main limitation of angio-CT is the use of the iodinated contrast media: these may be nephrotoxic in this category of patients, especially as it is tuclazepam followed

by endovascular treatment using arteriography, which uses the same type of contrast [71] and [72]. • PAD should be suspected and assessed in all diabetic subjects with foot ulcers. There are currently no published data concerning any medical treatment of PAD other than revascularisation. However, it is important to correct any modifiable risk factors for cardiovascular disease, especially perioperatively and during the follow-up. Prostanoid treatment (i.e., the intravenous infusion of a stable prostacyclin (PGI2) analogue such as iloprost/Alprostar for 3–4 weeks) is not an alternative to peripheral revascularisation in diabetic patients with PAD [73]. For ethical reasons, no randomised clinical trials have been carried out in order to compare the efficacy of prostanoid treatment with that of surgery in patients with critical ischaemia. However, it is important for relieving pain while awaiting surgical revascularisation, improving post-revascularisation perfusion and improving the patients’ quality of life [74].